8000 Background: Personalized medicine is now a reality for advanced NSCLC pts on the
basis of routine screening for EGFR mutation and ALK gene fusion assessment. The French …

Lung cancer continues to be a major global health problem; the disease is diagnosed in more
than 1.6 million new patients each year. However, significant progress is underway in both …

Wnt signaling has recently emerged as a critical pathway in lung carcinogenesis as already
demonstrated in many cancers and particularly in colorectal cancer. We critically discuss in …

Dermatologic irAEs induced by PD-1 or PD-L1 blockade therapy rarely result in significant
morbidity or permanent discontinuation of treatment. However, early recognition and …

7500 Background: MPM median overall survival (OS) did not exceed 13 months with
pemetrexed-platinum doublet, with virtually no surviving patients at 5 years. Vascular endothelial …

Tolyporphin (TP), a porphyrin extracted from cyanobacteria, was found to be a very potent
photosensitizer of EMT-6 tumor cells grown both in vitro as suspensions or monolayers and in …

Background Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to
treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across …

Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …

Background The molecular profiling of patients with advanced non-small-cell lung cancer (NSCLC)
for known oncogenic drivers is recommended during routine care. Nationally, …

Purpose Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1
rearrangement. Crizotinib is a potent inhibitor of both ROS1 and ALK kinase domains. Patients and …